Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Core Insights - Nuvalent, Inc. announced the presentation of patient-reported outcomes data and pivotal efficacy and safety data from the ARROS-1 trial of zidesamtinib at the 2025 IASLC ASCO North America Conference on Lung Cancer [1][2] Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, specifically designed to overcome limitations of existing treatments for kinase targets [5] - The company is advancing a pipeline that includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [5] Zidesamtinib and ARROS-1 Trial - Zidesamtinib is an investigational ROS1-selective inhibitor aimed at overcoming resistance seen with current ROS1 inhibitors and is designed for central nervous system (CNS) penetrance [3] - The ARROS-1 trial is a first-in-human Phase 1/2 clinical trial for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors, with the Phase 1 portion focusing on safety and tolerability [4] - The ongoing Phase 2 portion of the trial is designed for TKI-naïve and TKI pre-treated patients with advanced ROS1-positive NSCLC, with registrational intent [4] Upcoming Presentations - Two poster presentations are scheduled for December 6, 2025, focusing on patient-reported outcomes and pivotal efficacy and safety data from the ARROS-1 trial [2]